Dmytro G. Rekalov
Zaporozhe, Ukraine
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis.
Journal: Archives of osteoporosis
Published: December 30, 2024
Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52.
Journal: The Journal of dermatological treatment
Published: December 10, 2024
A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis.
Journal: Journal of the American Academy of Dermatology
Published: January 26, 2024
Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis.
Journal: Arthritis care & research
Published: July 17, 2018
Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
Journal: mAbs
Published: July 17, 2018
NEPHROPATHY IN EARLY RHEUMATOID ARTHRITIS PATIENTS: DOES A SIGNIFICANT RISK EXIST?
Journal: Georgian medical news
Published: February 21, 2018
CLINICAL SIGNIFICANCE OF BIOMARKERS OF OSTEOCHONDRAL LESIONS IN EARLY RHEUMATOID ARTHRITIS
Journal: Georgian medical news
Published: November 16, 2016
Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial.
Journal: Annals of the rheumatic diseases
Published: November 20, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026